Skip to main content

Advertisement

SpringerLink
Log in

Arterial Stiffness and the Canonical WNT/β-catenin Pathway

  • Mechanisms of Hypertension and Target-Organ Damage (JE Hall and ME Hall, Section Editors)
  • Published:
Current Hypertension Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Arterial stiffness (AS) was mainly associated with cardiovascular morbidity and mortality in a hypertensive patient. Some risk factors contribute to the development of AS, such as aging, high blood pressure, vascular calcification, inflammation, and diabetes mellitus. The WNT/β-catenin pathway is implicated in numerous signaling and regulating pathways, including embryogenesis, cell proliferation, migration and polarity, apoptosis, and organogenesis. The activation of the WNT/β-catenin pathway is associated with the development of these risk factors.

Recent Findings

Aortic pulse wave velocity (PWV) is measured to determine AS, and in peripheral artery disease patients, PWV is higher than controls. An augmentation in PWV by 1 m/s has been shown to increase the risk of cardiovascular events by 14%. AS measured by PWV is characterized by the deregulation of the WNT/β-catenin pathway by the inactivation of its two inhibitors, i.e., DKK1 and sclerostin.

Summary

Thus, this review focuses on the role of the WNT/β-catenin pathway which contributes to the development of arterial stiffness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

Acetyl-coA:

Acetyl-coenzyme A

APC:

Adenomatous polyposis coli

ECM:

Extracellular matrix

FZD:

Frizzled

GSK-3β:

Glycogen synthase kinase-3β

LRP 5/6:

Low-density lipoprotein receptor-related protein 5/6

NF-ϰB:

Nuclear factor kappaB

TCF/LEF:

T-cell factor/lymphoid enhancer factor

TNF-α:

Tumor necrosis factor alpha

VSMC:

Vascular smooth muscle cell

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. O’Shea PM, Griffin TP, Fitzgibbon M. Hypertension: the role of biochemistry in the diagnosis and management. Clin Chim Acta Int J Clin Chem. 2017;465:131–43.

    Article  Google Scholar 

  2. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318–27.

    Article  PubMed  Google Scholar 

  3. Kubozono T, Ohishi M. Prognostic significance of regional arterial stiffness for stroke in hypertension. Pulse Basel Switz. 2015;3:98–105.

    Article  Google Scholar 

  4. Vallée A, Cinaud A, Protogerou A, Zhang Y, Topouchian J, Safar ME, et al. Arterial stiffness and coronary ischemia: new aspects and paradigms. Curr Hypertens Rep. 2020;22:5.

    Article  PubMed  Google Scholar 

  5. Humphrey JD, Harrison DG, Figueroa CA, Lacolley P, Laurent S. Central artery stiffness in hypertension and aging: a problem with cause and consequence. Circ Res. 2016;118:379–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Palombo C, Kozakova M. Arterial stiffness, atherosclerosis and cardiovascular risk: pathophysiologic mechanisms and emerging clinical indications. Vascul Pharmacol. 2016;77:1–7.

    Article  CAS  PubMed  Google Scholar 

  7. Vallée A, Lévy BL, Blacher J. Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension. Curr Hypertens Rep. 2018;20:62.

    Article  PubMed  Google Scholar 

  8. Cai T, Sun D, Duan Y, Wen P, Dai C, Yang J, et al. WNT/β-catenin signaling promotes VSMCs to osteogenic transdifferentiation and calcification through directly modulating Runx2 gene expression. Exp Cell Res. 2016;345:206–17.

    Article  CAS  PubMed  Google Scholar 

  9. Ma S, Yao S, Tian H, Jiao P, Yang N, Zhu P, et al. Pigment epithelium-derived factor alleviates endothelial injury by inhibiting Wnt/β-catenin pathway. Lipids Health Dis. 2017;16:31.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Anderson TJ. Arterial stiffness or endothelial dysfunction as a surrogate marker of vascular risk. Can J Cardiol. 2006;22(Suppl B):72B-80B.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588–605.

    Article  PubMed  Google Scholar 

  12. • Catalano M, Scandale G, Carzaniga G, Cinquini M, Minola M, Dimitrov G, et al. Increased aortic stiffness and related factors in patients with peripheral arterial disease. J Clin Hypertens Greenwich Conn. 2013;15:712–6.

    Article  Google Scholar 

  13. Janić M, Lunder M, Sabovič M. Arterial stiffness and cardiovascular therapy. BioMed Res Int. 2014;2014:621437.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Mozos I, Luca CT. Crosstalk between oxidative and nitrosative stress and arterial stiffness. Curr Vasc Pharmacol. 2017;15:446–56.

    Article  CAS  PubMed  Google Scholar 

  15. Ismaeel A, Brumberg RS, Kirk JS, Papoutsi E, Farmer PJ, Bohannon WT, et al. Oxidative Stress and arterial dysfunction in peripheral artery disease. Antioxid Basel Switz. 2018;7:E145.

    Article  Google Scholar 

  16. Zanoli L, Rastelli S, Inserra G, Castellino P. Arterial structure and function in inflammatory bowel disease. World J Gastroenterol. 2015;21:11304–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Kals J, Kampus P, Kals M, Pulges A, Teesalu R, Zilmer K, et al. Inflammation and oxidative stress are associated differently with endothelial function and arterial stiffness in healthy subjects and in patients with atherosclerosis. Scand J Clin Lab Invest. 2008;68:594–601.

    Article  CAS  PubMed  Google Scholar 

  18. Zagura M, Kals J, Kilk K, Serg M, Kampus P, Eha J, et al. Metabolomic signature of arterial stiffness in male patients with peripheral arterial disease. Hypertens Res Off J Jpn Soc Hypertens. 2015;38:840–6.

    Article  CAS  Google Scholar 

  19. •• Loh KM, van Amerongen R, Nusse R. Generating cellular diversity and spatial form: Wnt signaling and the evolution of multicellular animals. Dev Cell. 2016;38:643–55.

    Article  CAS  PubMed  Google Scholar 

  20. Oren O, Smith BD. Eliminating cancer stem cells by targeting embryonic signaling pathways. Stem Cell Rev. 2017;13:17–23.

    Article  CAS  Google Scholar 

  21. Al-Harthi L. Wnt/β-catenin and its diverse physiological cell signaling pathways in neurodegenerative and neuropsychiatric disorders. J Neuroimmune Pharmacol. 2012;7:725–30.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Marchetti B, Pluchino S. Wnt your brain be inflamed? Yes, it Wnt! Trends Mol Med. 2013;19:144–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Vallée A, Vallée J-N, Lecarpentier Y. Metabolic reprogramming in atherosclerosis: opposed interplay between the canonical WNT/β-catenin pathway and PPARγ. J Mol Cell Cardiol. 2019;133:36–46.

    Article  PubMed  Google Scholar 

  24. Lecarpentier Y, Schussler O, Hébert J-L, Vallée A. Molecular mechanisms underlying the circadian rhythm of blood pressure in normotensive subjects. Curr Hypertens Rep. 2020;22:50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281:1509–12.

    Article  CAS  PubMed  Google Scholar 

  26. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D’Amico M, Pestell R, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999;96:5522–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol [Internet]. 2009 [cited 2017 Apr 7]; Available from: http://www.nature.com/doifinder/10.1038/nrm2717.

  28. Sharma C, Pradeep A, Wong L, Rana A, Rana B. Peroxisome proliferator-activated receptor gamma activation can regulate beta-catenin levels via a proteasome-mediated and adenomatous polyposis coli-independent pathway. J Biol Chem. 2004;279:35583–94.

    Article  CAS  PubMed  Google Scholar 

  29. Rosi MC, Luccarini I, Grossi C, Fiorentini A, Spillantini MG, Prisco A, et al. Increased Dickkopf-1 expression in transgenic mouse models of neurodegenerative disease. J Neurochem. 2010;112:1539–51.

    Article  CAS  PubMed  Google Scholar 

  30. Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell. 2012;149:1192–205.

    Article  CAS  PubMed  Google Scholar 

  31. Inestrosa NC, Montecinos-Oliva C, Fuenzalida M. Wnt signaling: role in Alzheimer disease and schizophrenia. J Neuroimmune Pharmacol Off J Soc NeuroImmune Pharmacol. 2012;7:788–807.

    Article  Google Scholar 

  32. Vallée A, Lecarpentier Y, Guillevin R, Vallée J-N. Interactions between TGF-β1, canonical WNT/β-catenin pathway and PPAR γ in radiation-induced fibrosis. Oncotarget. 2017;8:90579–604.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Vallée A, Lecarpentier Y, Vallée J-N. Hypothesis of opposite interplay between the canonical WNT/beta-catenin pathway and PPAR gamma in primary central nervous system lymphomas. Curr Issues Mol Biol. 2019;31:1–20.

    Article  PubMed  Google Scholar 

  34. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β-catenin is a target for the ubiquitin–proteasome pathway. EMBO J. 1997;16:3797–804.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Wu D, Pan W. GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem Sci. 2010;35:161–8.

    Article  CAS  PubMed  Google Scholar 

  36. Hur E-M, Zhou F-Q. GSK3 signalling in neural development. Nat Rev Neurosci. 2010;11:539–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Ambacher KK, Pitzul KB, Karajgikar M, Hamilton A, Ferguson SS, Cregan SP. The JNK- and AKT/GSK3β-signaling pathways converge to regulate puma induction and neuronal apoptosis induced by trophic factor deprivation. Hetman M, editor. PLoS ONE. 2012;7:e46885.

  38. van de Schans VAM, Smits JFM, Blankesteijn WM. The Wnt/frizzled pathway in cardiovascular development and disease: friend or foe? Eur J Pharmacol. 2008;585:338–45.

    Article  PubMed  Google Scholar 

  39. Tian Y, Cohen ED, Morrisey EE. The importance of Wnt signaling in cardiovascular development. Pediatr Cardiol. 2010;31:342–8.

    Article  PubMed  Google Scholar 

  40. Shao J-S, Aly ZA, Lai C-F, Cheng S-L, Cai J, Huang E, et al. Vascular Bmp Msx2 Wnt signaling and oxidative stress in arterial calcification. Ann N Y Acad Sci. 2007;1117:40–50.

    Article  CAS  PubMed  Google Scholar 

  41. Al-Aly Z. Arterial calcification: a tumor necrosis factor-alpha mediated vascular Wnt-opathy. Transl Res J Lab Clin Med. 2008;151:233–9.

    CAS  Google Scholar 

  42. Tsaousi A, Mill C, George SJ. The Wnt pathways in vascular disease: lessons from vascular development. Curr Opin Lipidol. 2011;22:350–7.

    Article  CAS  PubMed  Google Scholar 

  43. Marinou K, Christodoulides C, Antoniades C, Koutsilieris M. Wnt signaling in cardiovascular physiology. Trends Endocrinol Metab TEM. 2012;23:628–36.

    Article  CAS  PubMed  Google Scholar 

  44. Mill C, George SJ. Wnt signalling in smooth muscle cells and its role in cardiovascular disorders. Cardiovasc Res. 2012;95:233–40.

    Article  CAS  PubMed  Google Scholar 

  45. • Barrett HE, Van der Heiden K, Farrell E, Gijsen FJH, Akyildiz AC. Calcifications in atherosclerotic plaques and impact on plaque biomechanics. J Biomech. 2019;87:1–12.

    Article  PubMed  Google Scholar 

  46. Cheng S-L, Shao J-S, Behrmann A, Krchma K, Towler DA. Dkk1 and MSX2-Wnt7b signaling reciprocally regulate the endothelial-mesenchymal transition in aortic endothelial cells. Arterioscler Thromb Vasc Biol. 2013;33:1679–89.

    Article  CAS  PubMed  Google Scholar 

  47. Cheng S-L, Behrmann A, Shao J-S, Ramachandran B, Krchma K, Bello Arredondo Y, et al. Targeted reduction of vascular Msx1 and Msx2 mitigates arteriosclerotic calcification and aortic stiffness in LDLR-deficient mice fed diabetogenic diets. Diabetes. 2014;63:4326–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. • Kirton JP, Crofts NJ, George SJ, Brennan K, Canfield AE. Wnt/beta-catenin signaling stimulates chondrogenic and inhibits adipogenic differentiation of pericytes: potential relevance to vascular disease? Circ Res. 2007;101:581–9.

    Article  CAS  PubMed  Google Scholar 

  49. Cheng S-L, Shao J-S, Halstead LR, Distelhorst K, Sierra O, Towler DA. Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis. Circ Res. 2010;107:271–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Shao J-S, Sierra OL, Cohen R, Mecham RP, Kovacs A, Wang J, et al. Vascular calcification and aortic fibrosis: a bifunctional role for osteopontin in diabetic arteriosclerosis. Arterioscler Thromb Vasc Biol. 2011;31:1821–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Yamashina A, Tomiyama H, Takeda K, Tsuda H, Arai T, Hirose K, et al. Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res Off J Jpn Soc Hypertens. 2002;25:359–64.

    Article  Google Scholar 

  52. Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, et al. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int. 2012;90:473–80.

    Article  CAS  PubMed  Google Scholar 

  53. Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone. 2013;56:42–7.

    Article  CAS  PubMed  Google Scholar 

  54. Yang H-Y, Wu D-A, Chen M-C, Hsu B-G. Correlation between sclerostin and Dickkopf-1 with aortic arterial stiffness in patients with type 2 diabetes: a prospective, cross-sectional study. Diab Vasc Dis Res. 2019;16:281–8.

    Article  CAS  PubMed  Google Scholar 

  55. Hsu B-G, Liou H-H, Lee C-J, Chen Y-C, Ho G-J, Lee M-C. Serum sclerostin as an independent marker of peripheral arterial stiffness in renal transplantation recipients: a cross-sectional study. Medicine (Baltimore). 2016;95:e3300.

    Article  Google Scholar 

  56. Gaudio A, Fiore V, Rapisarda R, Sidoti MH, Xourafa A, Catalano A, et al. Sclerostin is a possible candidate marker of arterial stiffness: results from a cohort study in Catania. Mol Med Rep. 2017;15:3420–4.

    Article  CAS  PubMed  Google Scholar 

  57. • Chang Y-C, Hsu B-G, Liou H-H, Lee C-J, Wang J-H. Serum levels of sclerostin as a potential biomarker in central arterial stiffness among hypertensive patients. BMC Cardiovasc Disord. 2018;18:214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Vallée A, Yannoutsos A, Temmar M, Dreyfuss Tubiana C, Spinu I, Zhang Y, et al. Determinants of the aortic pulse wave velocity index in hypertensive and diabetic patients: predictive and therapeutic implications. J Hypertens. 2018;36:2324–32.

    Article  PubMed  Google Scholar 

  59. Vallée A, Safar ME, Blacher J. Application of a decision tree to establish factors associated with a nomogram of aortic stiffness. J Clin Hypertens Greenwich Conn. 2019;21:1484–92.

    Article  Google Scholar 

  60. Vallée A, Lelong H, Lopez-Sublet M, Topouchian J, Safar ME, Blacher J. Association between different lipid parameters and aortic stiffness: clinical and therapeutic implication perspectives. J Hypertens. 2019;37:2240–6.

    Article  PubMed  Google Scholar 

  61. Vallée A, Olié V, Lelong HÉL, Kretz S, Safar ME, Blacher J. Relationship between BMI and aortic stiffness: influence of anthropometric indices in hypertensive men and women. J Hypertens. 2020;38:249–56.

    Article  PubMed  Google Scholar 

  62. Donato AJ, Gano LB, Eskurza I, Silver AE, Gates PE, Jablonski K, et al. Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol. 2009;297:H425-432.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Lesniewski LA, Connell ML, Durrant JR, Folian BJ, Anderson MC, Donato AJ, et al. B6D2F1 mice are a suitable model of oxidative stress-mediated impaired endothelium-dependent dilation with aging. J Gerontol A Biol Sci Med Sci. 2009;64:9–20.

    Article  PubMed  Google Scholar 

  64. Naghavi M, Yen AA, Lin AWH, Tanaka H, Kleis S. New indices of endothelial function measured by digital thermal monitoring of vascular reactivity: data from 6084 patients registry. Int J Vasc Med. 2016;2016:1348028.

    PubMed  PubMed Central  Google Scholar 

  65. Furuhashi M, Yuda S, Muranaka A, Kawamukai M, Matsumoto M, Tanaka M, et al. Circulating fatty acid-binding protein 4 concentration predicts the progression of carotid atherosclerosis in a general population without medication. Circ J Off J Jpn Circ Soc. 2018;82:1121–9.

    CAS  Google Scholar 

  66. Jean G, Chazot C, Bresson E, Zaoui E, Cavalier E. High serum sclerostin levels are associated with a better outcome in haemodialysis patients. Nephron. 2016;132:181–90.

    Article  CAS  PubMed  Google Scholar 

  67. London GM, Safar ME, Pannier B. Aortic aging in ESRD: structural, hemodynamic, and mortality implications. J Am Soc Nephrol JASN. 2016;27:1837–46.

    Article  PubMed  Google Scholar 

  68. Hou J-S, Lin Y-L, Wang C-H, Lai Y-H, Kuo C-H, Subeq Y-M, et al. Serum osteoprotegerin is an independent marker of central arterial stiffness as assessed using carotid-femoral pulse wave velocity in hemodialysis patients: a cross sectional study. BMC Nephrol. 2019;20:184.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Wu C-F, Hou J-S, Wang C-H, Lin Y-L, Lai Y-H, Kuo C-H, et al. Serum sclerostin but not DKK-1 correlated with central arterial stiffness in end stage renal disease patients. Int J Environ Res Public Health. 2020;17:E1230.

    Article  PubMed  Google Scholar 

  70. Gong J, Xie Q, Han Y, Chen B, Li L, Zhou G, et al. Relationship between components of metabolic syndrome and arterial stiffness in Chinese hypertensives. Clin Exp Hypertens N Y N. 1993;2020(42):146–52.

    Google Scholar 

  71. Levisianou D, Melidonis A, Adamopoulou E, Skopelitis E, Koutsovasilis A, Protopsaltis I, et al. Impact of the metabolic syndrome and its components combinations on arterial stiffness in Type 2 diabetic men. Int Angiol J Int Union Angiol. 2009;28:490–5.

    CAS  Google Scholar 

  72. Tseng P-W, Hou J-S, Wu D-A, Hsu B-G. High serum adipocyte fatty acid binding protein concentration linked with increased aortic arterial stiffness in patients with type 2 diabetes. Clin Chim Acta Int J Clin Chem. 2019;495:35–9.

    Article  CAS  Google Scholar 

  73. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153:1194–217.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Cheon SS, Nadesan P, Poon R, Alman BA. Growth factors regulate beta-catenin-mediated TCF-dependent transcriptional activation in fibroblasts during the proliferative phase of wound healing. Exp Cell Res. 2004;293:267–74.

    Article  CAS  PubMed  Google Scholar 

  75. Vallée A, Lecarpentier Y, Vallée J-N. Thermodynamic aspects and reprogramming cellular energy metabolism during the fibrosis process. Int J Mol Sci. 2017;18.

  76. Surendran K, Simon TC. CNP gene expression is activated by Wnt signaling and correlates with Wnt4 expression during renal injury. Am J Physiol Renal Physiol. 2003;284:F653-662.

    Article  CAS  PubMed  Google Scholar 

  77. Vallée A, Lecarpentier Y, Guillevin R, Vallée J-N. Aerobic glycolysis hypothesis through WNT/beta-catenin pathway in exudative age-related macular degeneration. J Mol Neurosci MN. 2017;62:368–79.

    Article  PubMed  Google Scholar 

  78. Vallée A, Lecarpentier Y, Vallée R, Guillevin R, Vallée J-N. Circadian rhythms in exudative age-related macular degeneration: the key role of the canonical WNT/β-Catenin Pathway. Int J Mol Sci. 2020;21:E820.

    Article  PubMed  Google Scholar 

  79. Vallée A, Lecarpentier Y, Guillevin R, Vallée J-N. Thermodynamics in neurodegenerative diseases: interplay between canonical WNT/beta-catenin pathway-PPAR gamma, energy metabolism and circadian rhythms. Neuromolecular Med. 2018;20:174–204.

    Article  PubMed  Google Scholar 

  80. Berwick DC, Harvey K. The regulation and deregulation of Wnt signaling by PARK genes in health and disease. J Mol Cell Biol. 2014;6:3–12.

    Article  PubMed  Google Scholar 

  81. Vallée A, Vallée J-N, Lecarpentier Y. Parkinson’s disease: potential actions of lithium by targeting the WNT/β-catenin pathway, oxidative stress, inflammation and glutamatergic pathway. Cells. 2021;10.

  82. Vallée A, Vallée J-N, Lecarpentier Y. Potential role of cannabidiol in Parkinson’s disease by targeting the WNT/β-catenin pathway, oxidative stress and inflammation. Aging. 2021;13:10796–813.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Vallée A, Lecarpentier Y. Alzheimer disease: crosstalk between the canonical Wnt/beta-catenin pathway and PPARs alpha and gamma. Front Neurosci. 2016;10:459.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Vallée A, Lecarpentier Y, Guillevin R, Vallée J-N. Reprogramming energetic metabolism in Alzheimer’s disease. Life Sci. 2018;193:141–52.

    Article  PubMed  Google Scholar 

  85. Brack AS, Conboy MJ, Roy S, Lee M, Kuo CJ, Keller C, et al. Increased Wnt signaling during aging alters muscle stem cell fate and increases fibrosis. Science. 2007;317:807–10.

    Article  CAS  PubMed  Google Scholar 

  86. •• García-Velázquez L, Arias C. The emerging role of Wnt signaling dysregulation in the understanding and modification of age-associated diseases. Ageing Res Rev. 2017;37:135–45.

    Article  PubMed  Google Scholar 

  87. Laurent S, Boutouyrie P. Arterial stiffness: a new surrogate end point for cardiovascular disease? J Nephrol. 2007;20(Suppl 12):S45-50.

    PubMed  Google Scholar 

  88. Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertens Dallas Tex. 1979;2009(54):1328–36.

    Google Scholar 

  89. Shirwany NA, Zou M. Arterial stiffness: a brief review. Acta Pharmacol Sin. 2010;31:1267–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Ramirez AJ, Christen AI, Sanchez RA. Serum uric acid elevation is associated to arterial stiffness in hypertensive patients with metabolic disturbances. Curr Hypertens Rev. 2018;14:154–60.

    Article  CAS  PubMed  Google Scholar 

  91. Tomiyama H, Shiina K. State of the art review: Brachial-Ankle PWV. J Atheroscler Thromb. 2020;27:621–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Tsai J-P, Hsu B-G. Arterial stiffness: a brief review. Tzu Chi Med J. 2021;33:115–21.

    Article  PubMed  Google Scholar 

  93. Wain LV, Verwoert GC, O’Reilly PF, Shi G, Johnson T, Johnson AD, et al. Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet. 2011;43:1005–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Abou Ziki MD, Mani A. Wnt signaling, a novel pathway regulating blood pressure? State of the art review Atherosclerosis. 2017;262:171–8.

    Article  CAS  PubMed  Google Scholar 

  95. Sarzani R, Salvi F, Bordicchia M, Guerra F, Battistoni I, Pagliariccio G, et al. Carotid artery atherosclerosis in hypertensive patients with a functional LDL receptor-related protein 6 gene variant. Nutr Metab Cardiovasc Dis NMCD. 2011;21:150–6.

    Article  CAS  PubMed  Google Scholar 

  96. Delgado-Lista J, Perez-Martinez P, García-Rios A, Phillips CM, Williams CM, Gulseth HL, et al. Pleiotropic effects of TCF7L2 gene variants and its modulation in the metabolic syndrome: from the LIPGENE study. Atherosclerosis. 2011;214:110–6.

    Article  CAS  PubMed  Google Scholar 

  97. Sumida T, Naito AT, Nomura S, Nakagawa A, Higo T, Hashimoto A, et al. Complement C1q-induced activation of β-catenin signalling causes hypertensive arterial remodelling. Nat Commun. 2015;6:6241.

    Article  CAS  PubMed  Google Scholar 

  98. Pauletto P, Sarzani R, Rappelli A, Chiavegato A, Pessina AC, Sartore S. Differentiation and growth of vascular smooth muscle cells in experimental hypertension. Am J Hypertens. 1994;7:661–74.

    Article  CAS  PubMed  Google Scholar 

  99. Kontaraki JE, Marketou ME, Zacharis EA, Parthenakis FI, Vardas PE. Differential expression of vascular smooth muscle-modulating microRNAs in human peripheral blood mononuclear cells: novel targets in essential hypertension. J Hum Hypertens. 2014;28:510–6.

    Article  CAS  PubMed  Google Scholar 

  100. Moe SM, Chen NX. Mechanisms of vascular calcification in chronic kidney disease. J Am Soc Nephrol JASN. 2008;19:213–6.

    Article  CAS  PubMed  Google Scholar 

  101. Nakayama M, Kaizu Y, Nagata M, Ura Y, Ikeda H, Shimamoto S, et al. Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study. BMC Nephrol. 2013;14:22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:E10-17.

    Article  CAS  PubMed  Google Scholar 

  103. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int. 2004;66:2293–9.

    Article  CAS  PubMed  Google Scholar 

  104. Nakamura S, Ishibashi-Ueda H, Niizuma S, Yoshihara F, Horio T, Kawano Y. Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol CJASN. 2009;4:1892–900.

    Article  CAS  PubMed  Google Scholar 

  105. Hsu C-C, Hwang S-J, Wen C-P, Chang H-Y, Chen T, Shiu R-S, et al. High prevalence and low awareness of CKD in Taiwan: a study on the relationship between serum creatinine and awareness from a nationally representative survey. Am J Kidney Dis Off J Natl Kidney Found. 2006;48:727–38.

    Article  CAS  Google Scholar 

  106. Wen CP, Cheng TYD, Tsai MK, Chang YC, Chan HT, Tsai SP, et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet Lond Engl. 2008;371:2173–82.

    Article  Google Scholar 

  107. Wilkinson FL, Liu Y, Rucka AK, Jeziorska M, Hoyland JA, Heagerty AM, et al. Contribution of VCAF-positive cells to neovascularization and calcification in atherosclerotic plaque development. J Pathol. 2007;211:362–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Wang Y, Li Y-P, Paulson C, Shao J-Z, Zhang X, Wu M, et al. Wnt and the Wnt signaling pathway in bone development and disease. Front Biosci Landmark Ed. 2014;19:379–407.

    Article  PubMed  PubMed Central  Google Scholar 

  109. Sipilä K, Koivistoinen T, Moilanen L, Nieminen T, Reunanen A, Jula A, et al. Metabolic syndrome and arterial stiffness: the Health 2000 Survey. Metabolism. 2007;56:320–6.

    Article  PubMed  Google Scholar 

  110. Ioannou K, Stel VS, Dounousi E, Jager KJ, Papagianni A, Pappas K, et al. Inflammation, endothelial dysfunction and increased left ventricular mass in chronic kidney disease (CKD) patients: a longitudinal study. PLoS ONE. 2015;10:e0138461.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Lai Y-H, Wang C-H, Kuo C-H, Lin Y-L, Tsai J-P, Hsu B-G. Serum P-cresyl sulfate is a predictor of central arterial stiffness in patients on maintenance hemodialysis. Toxins. 2019;12:E10.

    Article  PubMed  Google Scholar 

  112. London GM. Arterial stiffness in chronic kidney disease and end-stage renal disease. Blood Purif. 2018;45:154–8.

    Article  PubMed  Google Scholar 

  113. Bessueille L, Magne D. Inflammation: a culprit for vascular calcification in atherosclerosis and diabetes. Cell Mol Life Sci CMLS. 2015;72:2475–89.

    Article  CAS  PubMed  Google Scholar 

  114. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res. 2008;79:360–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  115. Masuda M, Miyazaki-Anzai S, Levi M, Ting TC, Miyazaki M. PERK-eIF2α-ATF4-CHOP signaling contributes to TNFα-induced vascular calcification. J Am Heart Assoc. 2013;2:e000238.

    Article  PubMed  PubMed Central  Google Scholar 

  116. Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145:33–43.

    Article  PubMed  Google Scholar 

  117. Ikeda K, Souma Y, Akakabe Y, Kitamura Y, Matsuo K, Shimoda Y, et al. Macrophages play a unique role in the plaque calcification by enhancing the osteogenic signals exerted by vascular smooth muscle cells. Biochem Biophys Res Commun. 2012;425:39–44.

    Article  CAS  PubMed  Google Scholar 

  118. Zhao G, Xu M-J, Zhao M-M, Dai X-Y, Kong W, Wilson GM, et al. Activation of nuclear factor-kappa B accelerates vascular calcification by inhibiting ankylosis protein homolog expression. Kidney Int. 2012;82:34–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  119. • Wang X, Adhikari N, Li Q, Guan Z, Hall JL. The role of [beta]-transducin repeat-containing protein ([beta]-TrCP) in the regulation of NF-[kappa]B in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2004;24:85–90.

    Article  PubMed  Google Scholar 

  120. Brunner EJ, Shipley MJ, Ahmadi-Abhari S, Tabak AG, McEniery CM, Wilkinson IB, et al. Adiposity, obesity, and arterial aging: longitudinal study of aortic stiffness in the Whitehall II cohort. Hypertens Dallas Tex. 1979;2015(66):294–300.

    Google Scholar 

  121. Yokoyama H, Kuramitsu M, Kanno S, Tada J, Yokota Y, Kamikawa F. Relationship between metabolic syndrome components and vascular properties in Japanese type 2 diabetic patients without cardiovascular disease or nephropathy. Diabetes Res Clin Pract. 2007;75:200–6.

    Article  CAS  PubMed  Google Scholar 

  122. Chen Y-C, Hsu B-G, Wang J-H, Lee C-J, Tsai J-P. Metabolic syndrome with aortic arterial stiffness and first hospitalization or mortality in coronary artery disease patients. Diabetes Metab Syndr Obes Targets Ther. 2019;12:2065–73.

    Article  CAS  Google Scholar 

  123. Schram MT, Henry RMA, van Dijk RAJM, Kostense PJ, Dekker JM, Nijpels G, et al. Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn study. Hypertens Dallas Tex. 1979;2004(43):176–81.

    Google Scholar 

  124. Semba RD, Najjar SS, Sun K, Lakatta EG, Ferrucci L. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am J Hypertens. 2009;22:74–9.

    Article  CAS  PubMed  Google Scholar 

  125. • Yapei Y, Xiaoyan R, Sha Z, Li P, Xiao M, Shuangfeng C, et al. Clinical significance of arterial stiffness and thickness biomarkers in type 2 diabetes mellitus: an up-to-date meta-analysis. Med Sci Monit Int Med J Exp Clin Res. 2015;21:2467–75.

    Google Scholar 

  126. Fujino T, Asaba H, Kang M-J, Ikeda Y, Sone H, Takada S, et al. Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci U S A. 2003;100:229–34.

    Article  CAS  PubMed  Google Scholar 

  127. Jin T. Current understanding on role of the Wnt signaling pathway effector TCF7L2 in glucose homeostasis. Endocr Rev. 2016;37:254–77.

    Article  CAS  PubMed  Google Scholar 

  128. Yao Y, Sun S, Wang J, Fei F, Dong Z, Ke A-W, et al. Canonical Wnt signaling remodels lipid metabolism in zebrafish hepatocytes following Ras oncogenic insult. Cancer Res. 2018;78:5548–60.

    Article  CAS  PubMed  Google Scholar 

  129. Xu W, Geng H, Liu X, Wang X, Li R, Lv Q, et al. Wingless-type MMTV integration site family member 5a: a novel biomarker regulated in type 2 diabetes mellitus and diabetic kidney disease. J Diabetes Metab Disord. 2019;18:525–32.

    Article  PubMed  PubMed Central  Google Scholar 

  130. Abou Azar F, Lim GE. Metabolic contributions of Wnt signaling: more than controlling flight. Front Cell Dev Biol. 2021;9:709823.

    Article  PubMed  PubMed Central  Google Scholar 

  131. Sanghera DK, Nath SK, Ortega L, Gambarelli M, Kim-Howard X, Singh JR, et al. TCF7L2 polymorphisms are associated with type 2 diabetes in Khatri Sikhs from North India: genetic variation affects lipid levels. Ann Hum Genet. 2008;72:499–509.

    Article  CAS  PubMed  Google Scholar 

  132. Muendlein A, Saely CH, Geller-Rhomberg S, Sonderegger G, Rein P, Winder T, et al. Single nucleotide polymorphisms of TCF7L2 are linked to diabetic coronary atherosclerosis. PLoS ONE. 2011;6:e17978.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Elhourch S, Arrouchi H, Mekkaoui N, Allou Y, Ghrifi F, Allam L, et al. Significant association of polymorphisms in the TCF7L2 gene with a higher risk of type 2 diabetes in a Moroccan population. J Pers Med. 2021;11:461.

    Article  PubMed  PubMed Central  Google Scholar 

  134. He QJ, Wang P, Liu QQ, Wu QG, Li YF, Wang J, et al. Secreted Wnt6 mediates diabetes-associated centrosome amplification via its receptor FZD4. Am J Physiol Cell Physiol. 2020;318:C48-62.

    Article  CAS  PubMed  Google Scholar 

  135. Chen Y, Hu Y, Zhou T, Zhou KK, Mott R, Wu M, et al. Activation of the Wnt pathway plays a pathogenic role in diabetic retinopathy in humans and animal models. Am J Pathol. 2009;175:2676–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  136. Toomes C, Bottomley HM, Jackson RM, Towns KV, Scott S, Mackey DA, et al. Mutations in LRP5 or FZD4 underlie the common familial exudative vitreoretinopathy locus on chromosome 11q. Am J Hum Genet. 2004;74:721–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Semënov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem. 2005;280:26770–5.

    Article  PubMed  Google Scholar 

  138. • Gaudio A, Privitera F, Battaglia K, Torrisi V, Sidoti MH, Pulvirenti I, et al. Sclerostin levels associated with inhibition of the Wnt/β-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97:3744–50.

    Article  CAS  PubMed  Google Scholar 

  139. Claes KJ, Viaene L, Heye S, Meijers B, d’Haese P, Evenepoel P. Sclerostin: another vascular calcification inhibitor? J Clin Endocrinol Metab. 2013;98:3221–8.

    Article  CAS  PubMed  Google Scholar 

  140. Hortells L, Sosa C, Guillén N, Lucea S, Millán Á, Sorribas V. Identifying early pathogenic events during vascular calcification in uremic rats. Kidney Int. 2017;92:1384–94.

    Article  CAS  PubMed  Google Scholar 

  141. Zhu D, Mackenzie NCW, Millán JL, Farquharson C, MacRae VE. The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS ONE. 2011;6:e19595.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev. 2012;33:747–83.

    Article  CAS  PubMed  Google Scholar 

  143. Evrard S, Delanaye P, Kamel S, Cristol J-P, Cavalier E, SFBC/SN joined working group on vascular calcifications. Vascular calcification: from pathophysiology to biomarkers. Clin Chim Acta Int J Clin Chem. 2015;438:401–14.

    Article  CAS  Google Scholar 

  144. Sehgel NL, Vatner SF, Meininger GA. “Smooth muscle cell stiffness syndrome”-revisiting the structural basis of arterial stiffness. Front Physiol. 2015;6:335.

    Article  PubMed  PubMed Central  Google Scholar 

  145. Pikilidou M, Yavropoulou M, Antoniou M, Yovos J. The contribution of osteoprogenitor cells to arterial stiffness and hypertension. J Vasc Res. 2015;52:32–40.

    Article  CAS  PubMed  Google Scholar 

  146. Kirkpantur A, Balci M, Turkvatan A, Afsar B. Independent association between serum sclerostin levels and carotid artery atherosclerosis in prevalent haemodialysis patients. Clin Kidney J. 2015;8:737–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Morena M, Jaussent I, Dupuy A-M, Bargnoux A-S, Kuster N, Chenine L, et al. Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2015;30:1345–56.

    CAS  Google Scholar 

  148. Wang X-R, Yuan L, Zhang J-J, Hao L, Wang D-G. Serum sclerostin values are associated with abdominal aortic calcification and predict cardiovascular events in patients with chronic kidney disease stages 3–5D. Nephrol Carlton Vic. 2017;22:286–92.

    Article  CAS  Google Scholar 

  149. Morales-Santana S, García-Fontana B, García-Martín A, Rozas-Moreno P, García-Salcedo JA, Reyes-García R, et al. Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care. 2013;36:1667–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology - Data - Biostatistics, Delegation of Clinical Research and Innovation, Foch Hospital, 92150, Suresnes, France

    Alexandre Vallée

Authors
  1. Alexandre Vallée
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The author listed has made a substantial, direct, and intellectual contribution to the work and approved it for publication.

Corresponding author

Correspondence to Alexandre Vallée.

Ethics declarations

Conflict of Interest

Alexandre Vallee declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Mechanisms of Hypertension and Target-Organ Damage

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vallée, A. Arterial Stiffness and the Canonical WNT/β-catenin Pathway. Curr Hypertens Rep 24, 499–507 (2022). https://doi.org/10.1007/s11906-022-01211-7

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11906-022-01211-7

Keywords

Search

Navigation